Cargando…
Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application
Immune checkpoint inhibitors (ICI) have emerged as a powerful oncologic treatment modality for patients with different solid tumors. Unfortunately, the efficacy of ICI monotherapy in ovarian cancer is limited, and combination therapy provides a new opportunity for immunotherapy in ovarian cancer. DN...
Autores principales: | Xie, Hongyu, Wang, Wenjie, Qi, Wencai, Jin, Weilin, Xia, Bairong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546337/ https://www.ncbi.nlm.nih.gov/pubmed/34712221 http://dx.doi.org/10.3389/fimmu.2021.661115 |
Ejemplares similares
-
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
por: Bao, Lei, et al.
Publicado: (2023) -
Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023) -
DNA Damage Repair in Brain Tumor Immunotherapy
por: Zhao, Shihong, et al.
Publicado: (2022) -
Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications
por: Wanderley, Carlos Wagner S., et al.
Publicado: (2022) -
Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume I
por: Di, Xiang-jie, et al.
Publicado: (2023)